Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Talphera Q3 2026 Results: Net Loss of $4.02M, Loss Narrows

For the nine months ended September 30, 2026, Talphera reported a net loss of $10.9 million, compared to a $10.5 million loss in the prior year period. Operating expenses increased to $12.0 million, driven by higher research and development costs related to the Niyad product candidate, while cash and short-term investments totaled $14.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-4.0-4.4
EPS (diluted, $ a share)$-0.05$-0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TLPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Talphera, Inc.: key numbers

Share price
$0.8609Close, Nov 16
Market cap
$44.7M
Shares outstanding
51.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Talphera, Inc.

All →
4:06 PM ET 8-K
Financial Results

Talphera Financial Results

Talphera reported a Q3 2026 net loss of $4.0 million and ended the quarter with $14.2 million in cash and investments. The company has submitted a briefing document to the FDA requesting to close enrollment for its pivotal NEPHRO CRRT study by year-end 2026, citing that current enrollment provides over 80% statistical power for the primary endpoint.

“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”

Vince Angotti, CEO of Talphera

“To date, we have enrolled more than 75% of the planned 70 patients. To support our goal of completing the study this year, we have submitted a briefing document to the FDA seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. While the study remains blinded and open for enrollment, we believe the current enrollment is sufficient to support a PMA filing as it has over 80% statistical power for the primary endpoint.”

Vince Angotti, CEO of Talphera

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.